Kindred Biosciences (KIN) Tops Q4 EPS by 1c

Kindred Biosciences (NASDAQ: KIN) reported Q4 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $951 thousand versus the consensus estimate of $1 million.

For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery